Results showed that treatment with the Bystolic-valsartan combination resulted in statistically significant reductions in diastolic blood pressure compared to Bystolic alone and valsartan alone. In ...

Forest Labs announced that it has submitted a New Drug Application (NDA) to the FDA for a once-daily, fixed dose combination (FDC) of nebivolol, a cardioselective beta-blocker and valsartan, an ...

Please provide your email address to receive an email when new articles are posted on . Actavis plc announced that it received a complete response letter from the FDA indicating that its fixed-dose ...

SILVER SPRING, MD — An FDA advisory panel has recommended by a six-to-four vote that a dual-agent medication combining a beta-blocker and an angiotensin-receptor blocker (ARB) not be approved for the ...

Although it is not mandatory, the FDA generally takes the recommendations of the advisory committee into account before approving a candidate. A final decision from the FDA on Actavis’ New Drug ...

June 27 (Reuters) - Forest Laboratories Inc said on Thursday that combining Bystolic, the brand name for nebivolol, and valsartan to treat hypertension in a clinical trial was more effective at ...

Forest Laboratories, Inc. ( FRX) recently presented positive topline data on its hypertension drug, Bystolic (nebivolol) when used in combination with valsartan. The 8-week randomized, double-blind, ...